• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanoparticle vaccine triggers immune system to fight multiple cancer types

April 24, 2017 By Sarah Faulkner

Nanoparticle vaccine
Photo courtesy of UT Southwestern

Researchers from the University of Texas Southwestern Medical Center have developed a nanoparticle vaccine immunotherapy that fights multiple cancer types, according to a preclinical study published in Nature Nanotechnology. 

The nanovaccine, which the team calls a 1st of its kind, is made up of tumor antigens inside of a synthetic polymer nanoparticle.

“What is unique about our design is the simplicity of the single-polymer composition that can precisely deliver tumor antigens to immune cells while stimulating innate immunity. These actions result in safe and robust production of tumor-specific T cells that kill cancer cells,” co-lead author Jinming Gao said in prepared remarks.

The newly published study demonstrated that the nanovaccine was effective in multiple tumor types in mice.

“For nanoparticle vaccines to work, they must deliver antigens to proper cellular compartments within specialized immune cells called antigen-presenting cells and stimulate innate immunity,” co-lead author Zhijian Chen said. “Our nanovaccine did all of those things.”

The nanovaccine activates an adaptor protein called STING, which triggers the body’s immune system to fight off cancer. The team applied their experimental vaccine to melanoma, colorectal cancer, and HPV-related cancers of the cervix, head, neck and anogenital regions of mice. They reported that in most cases, the nanovaccine slowed tumor growth and extended survival.

“Recent advances in understanding innate and adaptive immunity have also led to more collaborations between immunologists and nanotechnologists,” said Dr. Chen. “These partnerships are critical in propelling the rapid development of new generations of nanovaccines.”

The team said they are now focused on clinical testing of the STING-activating nanovaccines for an array of cancer indications, as well as potentially combining it with radiation or checkpoint inhibition.

Filed Under: Featured, Nanoparticles, Oncology, Preclinical Trials, Research & Development Tagged With: University of Texas Southwestern Medical Center

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS